<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05615558</url>
  </required_header>
  <id_info>
    <org_study_id>275134</org_study_id>
    <nct_id>NCT05615558</nct_id>
  </id_info>
  <brief_title>High-Protein Diets and Diabetes</brief_title>
  <acronym>HPD</acronym>
  <official_title>The Impact of a High-Protein Diet From Animal vs. Non-Animal Sources on Insulin Sensitivity and β-cell Function in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Exeter</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Marlow Foods Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Exeter</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High-protein (HP) diets are popular and evidence indicates they are more likely to be adhered&#xD;
      to and produce more sustained weight loss, particularly under ad libitum conditions. They&#xD;
      also improve glucose control and so may be helpful for treatment of Type 2 Diabetes (T2D),&#xD;
      particularly in the short-term, possibly via an improvement in insulin secretion. Indeed, HP&#xD;
      diets may be uniquely effective at promoting insulin secretion in T2D, but further research&#xD;
      is needed to understand why HP. Thus, there is an urgent need to determine how HP diets&#xD;
      affect T2D pathophysiology of insulin secretion and action using direct measures of β-cell&#xD;
      dysfunction and insulin sensitivity. It is also imperative to know how the type of protein&#xD;
      (animal vs. non-animal) affects insulin secretion in order to ultimately obtain an&#xD;
      environmentally and economically sustainable HP diet that can improve glucose control and T2D&#xD;
      pathophysiology in the long-term as well as providing patients with a greater choice for&#xD;
      dietary management of T2D.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2022</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>Change from Baseline insulin sensitivity after 5-week controlled diet</time_frame>
    <description>Rate of disappearance (Rd) during the hyperinsulinaemic-euglycaemic clamp from participants on each diet, a measure of insulin sensitivity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>β-cell function</measure>
    <time_frame>Change from Baseline β-cell function after 5-week controlled diet</time_frame>
    <description>β-cell function measured by modelling of glucose, insulin and c-peptide during MMTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose control</measure>
    <time_frame>Change from Baseline glucose control after 5-week controlled diet</time_frame>
    <description>Glucose control measured by fasting glucose, 2 hour MMTT glucose, 24-hour glucose profile using continuous glucose monitoring probe and HbA1c.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Branched-chain amino acid (BCAA) metabolism</measure>
    <time_frame>Change from Baseline BCAA after 1, 2, 3, 4 and 5 weeks of controlled diet</time_frame>
    <description>BCAA metabolism measured by plasma BCAA concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes treatment satisfaction measured by the diabetes treatment satisfaction questionnaire</measure>
    <time_frame>Change from Baseline treatment satisfaction after 5-week controlled diet</time_frame>
    <description>Treatment satisfaction measured by the diabetes treatment satisfaction questionnaire (DTSQ).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Animal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm of the study consuming a high-protein diet from animal sources.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-animal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm of the study consuming a high-protein diet from non-animal sources.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dietary Intervention</intervention_name>
    <description>Controlled dietary intervention; all food is provided to participants after being allocated to animal or non-animal dietary protein, for a duration of 5 weeks.</description>
    <arm_group_label>Animal</arm_group_label>
    <arm_group_label>Non-animal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 40-70 y&#xD;
&#xD;
          -  Body-mass index of 27-45 kg/m2&#xD;
&#xD;
          -  Diagnosed with T2D with their most recent HbA1c value greater than 6.0% (&gt;43 mmol/mol)&#xD;
             and receiving dietary advice and/or antidiabetic medication (metformin, DPP-4&#xD;
             inhibitors only).&#xD;
&#xD;
          -  Males and females&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Habitual dietary intake of &lt;0.6 or &gt;1.2 g/kg/day protein (determined from dietary&#xD;
             history interview given at screening)&#xD;
&#xD;
          -  Current use of insulin&#xD;
&#xD;
          -  HbA1c of 12% or more (≥108 mmol/mol)&#xD;
&#xD;
          -  Weight loss of more than 5 kg within the past 6 months&#xD;
&#xD;
          -  A recent estimated glomerular filtration rate (eGFR) of less than 30 mL/min,&#xD;
&#xD;
          -  Heart failure,&#xD;
&#xD;
          -  Participation in another clinical research trial, substance abuse, known cancer,&#xD;
             myocardial infarction within the previous 6 months, current treatment with&#xD;
             anti-obesity drugs, pregnancy or consideration of pregnancy, and hospital admission&#xD;
             for depression or use of antipsychotic drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gráinne Whelehan, BSc.</last_name>
    <phone>013922157</phone>
    <email>g.whelehan@exeter.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nutritional Physiology Research Unit</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX12LU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gráinne Whelehan, BSc.</last_name>
      <phone>013922157</phone>
      <email>g.whelehan@exeter.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>May 26, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 7, 2022</last_update_submitted>
  <last_update_submitted_qc>November 7, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

